| bradykinin receptor B1 | |||||||
|---|---|---|---|---|---|---|---|
| Identifiers | |||||||
| Symbol | BDKRB1 | ||||||
| NCBI gene | 623 | ||||||
| HGNC | 1029 | ||||||
| OMIM | 600337 | ||||||
| RefSeq | NM_000710 | ||||||
| UniProt | P46663 | ||||||
| Other data | |||||||
| Locus | Chr. 14q32.1-32.2 | ||||||
| |||||||
| bradykinin receptor B2 | |||||||
|---|---|---|---|---|---|---|---|
| Identifiers | |||||||
| Symbol | BDKRB2 | ||||||
| NCBI gene | 624 | ||||||
| HGNC | 1030 | ||||||
| OMIM | 113503 | ||||||
| RefSeq | NM_000623 | ||||||
| UniProt | P30411 | ||||||
| Other data | |||||||
| Locus | Chr. 14q32.1-32.2 | ||||||
| |||||||
Thebradykinin receptor family is a group ofG-protein coupled receptors whose principalligand is the proteinbradykinin.
There are two Bradykinin receptors: theB1 receptor and theB2 receptor.[1]
Bradykinin receptor B1 (B1) is a G-protein coupled receptor encoded by the BDKRB1 gene in humans. Its principal ligand is bradykinin, a 9 amino acid peptide generated in pathophysiologic conditions such as inflammation, trauma, burns, shock, and allergy. The B1 receptor is one of two G protein-coupled receptors that have been found which bind bradykinin and mediate responses to these pathophysiologic conditions.
B1 protein is synthesized by de novo following tissue injury and receptor binding leads to an increase in the cytosolic calcium ion concentration, ultimately resulting in chronic and acute inflammatory responses.
The B2 receptor is aG protein-coupled receptor, coupled toGq andGi. Gq stimulatesphospholipase C to increaseintracellular freecalcium and Gi inhibitsadenylate cyclase. Furthermore, the receptor stimulates themitogen-activated protein kinase pathways. It is ubiquitously and constitutively expressed in healthy tissues.
The B2 receptor forms a complex with angiotensin converting enzyme (ACE), and this is thought to play a role in cross-talk between the renin-angiotensin system (RAS) and thekinin–kallikrein system (KKS). The heptapeptideangiotensin (1-7) also potentiates bradykinin action on B2 receptors.[2]
Icatibant is a second generation B2 receptor antagonist which has undergone limited clinical trials in pain and inflammation. FR 173657 is another orally active non-peptide B2 antagonist that has undergone limited trials asanalgesic and antiinflammatory drug.
Kallidin also signals through the B2 receptor.